Advocates have claimed that CVS’s refusal to cover Yeztugo violates the Affordable Care Act (ACA), which requires insurers to ...

CVS Health will not cover Gilead's Yeztugo, generic name lenacapavir (LEN), citing "clinical, financial, and regulatory ...

CVS Health (NYSE:CVS), one of the leading health insurers in the U.S. and owner of the Pharmacy Benefit Manager Caremark, ...

CVS Health , which runs the largest U.S. pharmacy benefit manager, will not add Gilead Sciences' new HIV prevention drug to ...

In 2014, Caremark was accused of manipulating how drug costs were reported, prompting Aetna and SilverScript to submit false ...

The owner of the U.S.' largest pharmacy benefit manager is declining to cover Gilead Sciences’ long-acting HIV prevention ...

Primary care physicians and the state Senate’s health care point person are questioning a proposed partnership between Mass ...

CVS Health is not entitled to coverage from insurers, including AIG and Chubb , against thousands of lawsuits over its role ...

Through the power of strategic, well-built partnerships, CVS Health helps employees earn degrees — and at no cost to them.

CVS Health's troubles haven't been solely on the fundamental side. Indeed, shares have underperformed on the price charts, too, down 18% on a total return basis (price change plus dividends) so ...

CVS Health CVS 0.0% (NYSE: CVS) reported its Q3 results earlier this month, with revenues and earnings beating the street estimates, and we believe that CVS stock is undervalued, as discussed below.